• Events Calendar
0 Items
Patients Rising Now
  • Home
  • About
    • About Us
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
    • What You Can Do
    • Advocacy Master Class
    • 2022 Fly-In
  • Donate
Select Page
  • Home
  • About
    • About Us
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
    • What You Can Do
    • Advocacy Master Class
    • 2022 Fly-In
  • Donate

Patients Rising Now’s Comments on Oregon’s 1115 Waiver and Impact on Access

Jan 7, 2022 | FDA, Letters Submitted

The FDA’s Accelerated Approval Program provides a path for earlier approval of drugs being developed to treat serious diseases and address unmet medical need. The process allows the use of a surrogate endpoint—an indirect marker of clinical benefit that allows the drug to be approved and in the hands of patients earlier, while the company continues to conduct post-marketing “confirmatory trials” to establish the drug’s benefits. It is important to understand that the FDA has processes in place to remove the drug from the market in case clinical benefit is not established with confirmatory trials.

Read the Comment Letter

 

 

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave

Tags:

Categories

  • Access
  • Actions
  • California
  • Comment Letters
  • Copay Accumulators
  • Copay Assistance
  • COVID-19
  • Drug Costs
  • FDA
  • Featured
  • Featured Action
  • Federal Issues
  • Health Insurance
  • Health Policy
  • ICER
  • Illinois
  • Issues
  • Letters Submitted
  • Letters Supported
  • Massachusetts
  • Medicaid
  • Medicare
  • Medicare Part D
  • News
  • Op-Ed
  • Out of Pocket Costs
  • Pharmacy Benefit Managers
  • Podcast
  • Prescription Drugs
  • Press Releases
  • Public Statement
  • QALY
  • State Issues
  • Statements
  • Step Therapy
  • Surprise Billing
  • Terry's Hot Take
  • Uncategorized
  • Value Based Insurance Design
  • Value Frameworks
  • Virtual Advocacy Chat

Tags

21st Century Cures Act 340B Access to Care Advocacy Alzheimer's Biden Administration biosimilars Cancer cms Copay Accumulators copay assistance COVID-19 Vaccine drug costs Drug Manufacturing Drug Pricing drug rebate fail first FDA H.R.3 Healthcare Inequities Health Insurance hospital bills HR 3708 hsa ICER Insurance design Joe Biden Lupus medicare Part B medicare part D Nonmedical Switching open enrollment Out of Pocket Costs PBM PBMs pharmacy benefit managers Price Transparency Prior Authorization QALY Rare Disease Right to Repair Step Therapy Telehealth transparency Value Framework

Recent Posts

  • Guide for Commenting on ICER’s Draft Evidence Report on Treatments for Amyotrophic Lateral Sclerosis (ALS)
  • Patients on Capitol Hill: Season 3 | Episode 24
  • The Future of Pharmacies: Season 3 | Episode 23: 
  • Patient Access to Care in Jeopardy as Hospitals Face Staffing Shortfalls
  • The Power of Patient Data: Season 3 | Episode 22

Sign up for updates

Patients Rising Now

We are a 501c4 group dedicated to demanding transparency in health care.  We are part of the Patients Rising suite of programs and services.

700 12th St. NW 700, Suite 700
Washington, DC 20005

  • Privacy Policy
  • Sponsor Opportunities
  • Patients Rising
  • Facebook
  • Twitter
  • Instagram
All rights reserved. © 2022 Patients Rising Now